BioCorRx Announces BICX101 Preclinical Update; ASAM Attendance
BioCorRx Inc. (OTCMKTS:BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that is has received updated data from preclinical studies for BICX101, a sustained release, injectable naltrexone for the treatment of opioid abuse and alcoholism. The Company is pleased to announce that three different formulations were successful in reaching 28 days of sustained release of naltrexone. The Company also announced that it will have a booth in the exhibit...
View full press release